Zostavax Sales Data
|Rank 87||Current sales rank, all
Last updated: February 2014 (updated quarterly).
The following data shows Zostavax U.S. retail sales in Q4 2013 compared to previous quarters.
|Date Range||Sales Rank||Sales ($000)||Units (000)|
|Q4 2013||87 (12)||$202,240||15.17%||182||20.53%|
|Q3 2013||99 ()||$175,606||151|
|Q4 2012||70 (14)||$222,633||14.39%||223||10.95%|
|Q3 2012||84 ()||$194,633||201|
* Units refer to the number of packages sold.
|September 14, 2016||Experimental Shingles Vaccine Looks Quite Effective: Study|
|December 31, 2015||Asthma May Be Linked to Shingles Risk|
|December 15, 2015||Shingles Linked to Raised Heart Risks for Seniors, Study Finds|
|October 5, 2011||Health Tip: Getting the Shingles Vaccine|
|March 24, 2011||U.S. Shingles Vaccine Approval Expanded|
|January 12, 2011||Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease|
|January 12, 2011||Vaccine For Shingles Ailment Effective -- And Seldom Used, Study Says|
|January 11, 2011||Shingles Vaccine Looks Like a Safe Bet for Seniors: Study|
|May 14, 2010||New Large Study Results Confirm Safety Profile of Zostavax, Merck's Shingles Vaccine, in People Aged 60 or Older|
|February 8, 2010||Getting Shingles Vaccine Easier|